# A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

> **NCT00096941** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Solid Cancers

## Interventions

- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT00096941
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2015-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096941, "A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00096941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*